Rheumatoid arthritis, a chronic inflammatory disease that causes pain, swelling and loss of joint function, is said to affect an estimated 1.3 million Americans. Developing a new drug for rheumatoid arthritis, designed for use in early stages of the disease, is Rigel Pharmaceuticals Inc., a clinical-stage drug development company.
